glp-1 medications ozempic Drug Can Cause Rare, Potentially Blinding Side Effect, EMA Warns Mattson acquires Hyde Park Group,

(2024, May 17)

In the SUSTAIN 6 trial, over 3,297 patients with type 2 diabetes with established chronic kidney disease and/or cardiovascular disease underwent randomization to semaglutide or placebo and were followed for 2 years resulting in a 26% risk reduction in the combined endpoint of rate of cardiovascular disease, nonfatal myocardial infarction, or nonfatal stroke [47]

Ive been on the diet for a year and a half and as a practitioner, Im pretty ridiculous about this myself

Many patients experience improvement as their body adjusts to the medication, though some require ongoing management strategies

UNITE Indianapolis